{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T13:02:51Z","timestamp":1793278971148,"version":"4.5.0"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,17]],"date-time":"2023-09-17T00:00:00Z","timestamp":1694908800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003130","name":"Fonds Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["G099518N"],"award-info":[{"award-number":["G099518N"]}],"id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003130","name":"Fonds Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["FWO 1196522N"],"award-info":[{"award-number":["FWO 1196522N"]}],"id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004040","name":"KU Leuven","doi-asserted-by":"publisher","award":["C14\/19\/100"],"award-info":[{"award-number":["C14\/19\/100"]}],"id":[{"id":"10.13039\/501100004040","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010648","name":"UZ Leuven","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010648","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eBioMedicine"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.ebiom.2023.104817","type":"journal-article","created":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T13:12:09Z","timestamp":1696511529000},"page":"104817","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Changes in bone and mineral homeostasis after short-term androgen deprivation therapy with or without androgen receptor signalling inhibitor \u2013 substudy of a single-centre, double blind, randomised, placebo-controlled phase 2 trial"],"prefix":"10.1016","volume":"97","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6050-6677","authenticated-orcid":false,"given":"Karel","family":"David","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ga\u00ebtan","family":"Devos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick","family":"Narinx","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1079-2860","authenticated-orcid":false,"given":"Leen","family":"Antonio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wout","family":"Devlies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludo","family":"Deboel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dieter","family":"Schollaert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anton","family":"Eisenhauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Etienne","family":"Cavalier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Vanderschueren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Claessens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Joniau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4153-4757","authenticated-orcid":false,"given":"Brigitte","family":"Decallonne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ebiom.2023.104817_bib1","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"10.1016\/j.ebiom.2023.104817_bib2","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.eururo.2020.09.042","article-title":"EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer-2020 update. Part 1: screening, diagnosis, and local treatment with curative intent","volume":"79","author":"Mottet","year":"2021","journal-title":"Eur Urol"},{"issue":"8","key":"10.1016\/j.ebiom.2023.104817_bib3","doi-asserted-by":"crossref","first-page":"T19","DOI":"10.1530\/ERC-21-0098","article-title":"Androgen receptor signaling inhibitors: post-chemotherapy, pre-chemotherapy and now in castration-sensitive prostate cancer","volume":"28","author":"Mitsiades","year":"2021","journal-title":"Endocr Relat Cancer"},{"issue":"12","key":"10.1016\/j.ebiom.2023.104817_bib4","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/s41585-021-00514-9","article-title":"Neoadjuvant hormonal therapy before radical prostatectomy in high-risk prostate cancer","volume":"18","author":"Devos","year":"2021","journal-title":"Nat Rev Urol"},{"issue":"2","key":"10.1016\/j.ebiom.2023.104817_bib5","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1056\/NEJMoa041943","article-title":"Risk of fracture after androgen deprivation for prostate cancer","volume":"352","author":"Shahinian","year":"2005","journal-title":"N\u00a0Engl J Med"},{"issue":"31","key":"10.1016\/j.ebiom.2023.104817_bib6","doi-asserted-by":"crossref","first-page":"7897","DOI":"10.1200\/JCO.2004.00.6908","article-title":"Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer","volume":"23","author":"Smith","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.ebiom.2023.104817_bib7","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s00198-018-4722-3","article-title":"Patients with prostate cancer and androgen deprivation therapy have increased risk of fractures-a study from the fractures and fall injuries in the elderly cohort (FRAILCO)","volume":"30","author":"Wallander","year":"2019","journal-title":"Osteoporos Int"},{"issue":"2","key":"10.1016\/j.ebiom.2023.104817_bib8","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/s41391-020-00296-y","article-title":"Bone health effects of androgen-deprivation therapy and androgen receptor inhibitors in patients with nonmetastatic castration-resistant prostate cancer","volume":"24","author":"Hussain","year":"2020","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"11","key":"10.1016\/j.ebiom.2023.104817_bib9","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.25826","article-title":"Evaluation of fall and fracture risk among men with prostate cancer treated with androgen receptor inhibitors: a systematic review and meta-analysis","volume":"3","author":"Myint","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"8","key":"10.1016\/j.ebiom.2023.104817_bib10","doi-asserted-by":"crossref","first-page":"T39","DOI":"10.1530\/ERC-21-0118","article-title":"Second-generation hormonotherapy in prostate cancer and bone microenvironment","volume":"28","author":"Bouleftour","year":"2021","journal-title":"Endocr Relat Cancer"},{"issue":"5","key":"10.1016\/j.ebiom.2023.104817_bib11","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1111\/j.1464-410X.2012.11758.x","article-title":"Fracture after androgen deprivation therapy among men with a high baseline risk of skeletal complications","volume":"111","author":"Shao","year":"2013","journal-title":"BJU Int"},{"issue":"6","key":"10.1016\/j.ebiom.2023.104817_bib12","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1210\/jc.2011-3045","article-title":"Osteoporosis in men: an Endocrine Society clinical practice guideline","volume":"97","author":"Watts","year":"2012","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"43","key":"10.1016\/j.ebiom.2023.104817_bib13","doi-asserted-by":"crossref","first-page":"75646","DOI":"10.18632\/oncotarget.17980","article-title":"The prevention of fragility fractures in patients with non-metastatic prostate cancer: a position statement by the international osteoporosis foundation","volume":"8","author":"Cianferotti","year":"2017","journal-title":"Oncotarget"},{"issue":"5","key":"10.1016\/j.ebiom.2023.104817_bib15","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1002\/jbmr.4793","article-title":"Performance of FRAX in men with prostate cancer: a registry-based cohort study","volume":"38","author":"Ye","year":"2023","journal-title":"J\u00a0Bone Miner Res"},{"issue":"10","key":"10.1016\/j.ebiom.2023.104817_bib16","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.6004\/jnccn.2020.7576","article-title":"Contemporary population-based analysis of bone mineral density testing in men initiating androgen deprivation therapy for prostate cancer","volume":"18","author":"Hu","year":"2020","journal-title":"J\u00a0Natl Compr Canc Netw"},{"key":"10.1016\/j.ebiom.2023.104817_bib17","first-page":"13","article-title":"Utilization of bone densitometry for prediction and administration of bisphosphonates to prevent osteoporosis in patients with prostate cancer without bone metastases receiving antiandrogen therapy","volume":"7","author":"Holt","year":"2015","journal-title":"Cancer Manag Res"},{"issue":"12","key":"10.1016\/j.ebiom.2023.104817_bib18","doi-asserted-by":"crossref","first-page":"6410","DOI":"10.1210\/jc.2005-0183","article-title":"Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer","volume":"90","author":"Greenspan","year":"2005","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"10","key":"10.1016\/j.ebiom.2023.104817_bib19","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1111\/iju.14077","article-title":"Short-term impact of androgen deprivation therapy on bone strength in castration-sensitive prostate cancer","volume":"26","author":"Kimura","year":"2019","journal-title":"Int J Urol"},{"issue":"1","key":"10.1016\/j.ebiom.2023.104817_bib20","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1186\/s12885-018-4275-z","article-title":"Neoadjuvant degarelix with or without apalutamide followed by radical prostatectomy for intermediate and high-risk prostate cancer: ARNEO, a randomized, double blind, placebo-controlled trial","volume":"18","author":"Tosco","year":"2018","journal-title":"BMC Cancer"},{"issue":"6","key":"10.1016\/j.ebiom.2023.104817_bib21","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.eururo.2022.09.009","article-title":"ARNEO: a randomized phase II trial of neoadjuvant degarelix with or without apalutamide prior to radical prostatectomy for high-risk prostate cancer","volume":"83","author":"Devos","year":"2022","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.ebiom.2023.104817_bib22","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/0895-4356(92)90016-G","article-title":"A\u00a0chronic disease score from automated pharmacy data","volume":"45","author":"Von Korff","year":"1992","journal-title":"J\u00a0Clin Epidemiol"},{"key":"10.1016\/j.ebiom.2023.104817_bib23","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/7956951","article-title":"Free testosterone reflects metabolic as well as ovarian disturbances in subfertile oligomenorrheic women","volume":"2018","author":"Antonio","year":"2018","journal-title":"Int J Endocrinol"},{"issue":"26","key":"10.1016\/j.ebiom.2023.104817_bib24","doi-asserted-by":"crossref","first-page":"8569","DOI":"10.1007\/s00216-013-7259-5","article-title":"Sensitive routine liquid chromatography-tandem mass spectrometry method for serum estradiol and estrone without derivatization","volume":"405","author":"Pauwels","year":"2013","journal-title":"Anal Bioanal Chem"},{"issue":"10","key":"10.1016\/j.ebiom.2023.104817_bib25","doi-asserted-by":"crossref","first-page":"3666","DOI":"10.1210\/jcem.84.10.6079","article-title":"A\u00a0critical evaluation of simple methods for the estimation of free testosterone in serum","volume":"84","author":"Vermeulen","year":"1999","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"9","key":"10.1016\/j.ebiom.2023.104817_bib26","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A\u00a0new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1016\/j.ebiom.2023.104817_bib27","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1255\/ejms.1024","article-title":"Development of a method for the quantification of 1alpha,25(OH)2-vitamin D3 in serum by liquid chromatography tandem mass spectrometry without derivatization","volume":"16","author":"Casetta","year":"2010","journal-title":"Eur J Mass Spectrom (Chichester)"},{"key":"10.1016\/j.ebiom.2023.104817_bib28","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.bone.2015.06.018","article-title":"Calcium and bone homeostasis in heterozygous carriers of CYP24A1 mutations: a cross-sectional study","volume":"81","author":"Cools","year":"2015","journal-title":"Bone"},{"issue":"6","key":"10.1016\/j.ebiom.2023.104817_bib29","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1210\/endo-102-6-1710","article-title":"Immunochemical measurement of the vitamin D-binding protein in rat serum","volume":"102","author":"Bouillon","year":"1978","journal-title":"Endocrinology"},{"key":"10.1016\/j.ebiom.2023.104817_bib30","article-title":"Calcium isotope ratios in blood and urine: a new biomarker for the diagnosis of osteoporosis","volume":"10","author":"Eisenhauer","year":"2019","journal-title":"Bone Rep"},{"issue":"3","key":"10.1016\/j.ebiom.2023.104817_bib31","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.kint.2022.04.024","article-title":"Naturally occurring stable calcium isotope ratios are a novel biomarker of bone calcium balance in chronic kidney disease","volume":"102","author":"Shroff","year":"2022","journal-title":"Kidney Int"},{"issue":"1","key":"10.1016\/j.ebiom.2023.104817_bib32","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1002\/jbmr.4158","article-title":"Naturally occurring stable calcium isotope ratios in body compartments provide a novel biomarker of bone mineral balance in children and young adults","volume":"36","author":"Shroff","year":"2021","journal-title":"J\u00a0Bone Miner Res"},{"issue":"2","key":"10.1016\/j.ebiom.2023.104817_bib33","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1530\/EJE-20-0348","article-title":"Early effects of androgen deprivation on bone and mineral homeostasis in adult men: a prospective cohort study","volume":"183","author":"Khalil","year":"2020","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"10.1016\/j.ebiom.2023.104817_bib34","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1210\/edrv.23.3.0465","article-title":"Sex steroids and the construction and conservation of the adult skeleton","volume":"23","author":"Riggs","year":"2002","journal-title":"Endocr Rev"},{"issue":"3","key":"10.1016\/j.ebiom.2023.104817_bib35","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1210\/endrev\/bnac031","article-title":"Bone turnover markers: basic biology to clinical applications","volume":"44","author":"Schini","year":"2022","journal-title":"Endocr Rev"},{"issue":"1","key":"10.1016\/j.ebiom.2023.104817_bib36","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1152\/physrev.00033.2015","article-title":"Estrogens and androgens in skeletal physiology and pathophysiology","volume":"97","author":"Almeida","year":"2017","journal-title":"Physiol Rev"},{"issue":"3","key":"10.1016\/j.ebiom.2023.104817_bib37","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1172\/JCI84137","article-title":"Gonadal steroid-dependent effects on bone turnover and bone mineral density in men","volume":"126","author":"Finkelstein","year":"2016","journal-title":"J\u00a0Clin Invest"},{"issue":"12","key":"10.1016\/j.ebiom.2023.104817_bib38","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1172\/JCI10942","article-title":"Relative contributions of testosterone and estrogen in regulating bone resorption and formation in normal elderly men","volume":"106","author":"Falahati-Nini","year":"2000","journal-title":"J\u00a0Clin Invest"},{"issue":"12","key":"10.1016\/j.ebiom.2023.104817_bib39","doi-asserted-by":"crossref","first-page":"E456","DOI":"10.1210\/jc.2010-0902","article-title":"Structural decay of bone microarchitecture in men with prostate cancer treated with androgen deprivation therapy","volume":"95","author":"Hamilton","year":"2010","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.ebiom.2023.104817_bib40","first-page":"355","article-title":"Pituitary-testicular function of prostatic cancer patients during treatment with a gonadotropin-releasing hormone agonist analog. I. Circulating hormone levels","volume":"8","author":"Huhtaniemi","year":"1987","journal-title":"J\u00a0Androl"},{"issue":"1","key":"10.1016\/j.ebiom.2023.104817_bib41","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1124\/jpet.301.1.95","article-title":"Pharmacological profile of a new, potent, and long-acting gonadotropin-releasing hormone antagonist: degarelix","volume":"301","author":"Broqua","year":"2002","journal-title":"J\u00a0Pharmacol Exp Ther"},{"issue":"12","key":"10.1016\/j.ebiom.2023.104817_bib42","doi-asserted-by":"crossref","first-page":"3398","DOI":"10.1210\/clinem\/dgac489","article-title":"Effect of degarelix administration on bone health in prostate cancer patients without bone metastases. The Blade Study","volume":"107","author":"Palumbo","year":"2022","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.ebiom.2023.104817_bib43","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1007\/s00198-013-2462-y","article-title":"Sclerostin serum levels in prostate cancer patients and their relationship with sex steroids","volume":"25","author":"Garc\u00eda-Fontana","year":"2014","journal-title":"Osteoporos Int"},{"issue":"13","key":"10.1016\/j.ebiom.2023.104817_bib44","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1200\/JCO.2004.01.174","article-title":"Bicalutamide monotherapy versus leuprolide monotherapy for prostate cancer: effects on bone mineral density and body composition","volume":"22","author":"Smith","year":"2004","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.ebiom.2023.104817_bib45","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s00198-007-0472-3","article-title":"The effect of combined androgen blockade on bone turnover and bone mineral density in men with prostate cancer","volume":"19","author":"Yamada","year":"2008","journal-title":"Osteoporos Int"},{"issue":"3-4","key":"10.1016\/j.ebiom.2023.104817_bib46","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.ghir.2012.04.003","article-title":"Deficiency in androgens and upregulation of insulin-like growth factor-1 are involved in high bone turnover in men receiving androgen deprivation therapy for prostate cancer","volume":"22","author":"Ishizaki","year":"2012","journal-title":"Growth Horm IGF Res"},{"issue":"5","key":"10.1016\/j.ebiom.2023.104817_bib47","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.eururo.2015.01.027","article-title":"Long-term efficacy and safety of enzalutamide monotherapy in hormone-na\u00efve prostate cancer: 1- and 2-year open-label follow-up results","volume":"68","author":"Tombal","year":"2015","journal-title":"Eur Urol"},{"issue":"15","key":"10.1016\/j.ebiom.2023.104817_bib48","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1056\/NEJMoa1715546","article-title":"Apalutamide treatment and metastasis-free survival in prostate cancer","volume":"378","author":"Smith","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.ebiom.2023.104817_bib49","doi-asserted-by":"crossref","first-page":"R111","DOI":"10.1530\/JOE-19-0077","article-title":"The effects of adjuvant endocrine therapy on bone health in women with breast cancer","volume":"241","author":"Ramchand","year":"2019","journal-title":"J\u00a0Endocrinol"}],"container-title":["eBioMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396423003833?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396423003833?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T19:36:46Z","timestamp":1778873806000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352396423003833"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":48,"alternative-id":["S2352396423003833"],"URL":"https:\/\/doi.org\/10.1016\/j.ebiom.2023.104817","relation":{},"ISSN":["2352-3964"],"issn-type":[{"value":"2352-3964","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Changes in bone and mineral homeostasis after short-term androgen deprivation therapy with or without androgen receptor signalling inhibitor \u2013 substudy of a single-centre, double blind, randomised, placebo-controlled phase 2 trial","name":"articletitle","label":"Article Title"},{"value":"eBioMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ebiom.2023.104817","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"104817"}}